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Comparison of Systemic and Mucosal Immunization with
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Abstract
Most HIV-1 infections are thought to occur at mucosal surfaces during sexual contact. It has been hypothesized that
vaccines delivered at mucosal surfaces may mediate better protection against HIV-1 than vaccines that are delivered
systemically. To test this, rhesus macaques were vaccinated by intramuscular (i.m.) or intravaginal (ivag.) routes with helperdependent adenoviral (HD-Ad) vectors expressing HIV-1 envelope. Macaques were first immunized intranasally with species
C Ad serotype 5 (Ad5) prior to serotype-switching with species C HD-Ad6, Ad1, Ad5, and Ad2 vectors expressing env
followed by rectal challenge with CCR5-tropic SHIV-SF162P3. Vaccination by the systemic route generated stronger systemic
CD8 T cell responses in PBMC, but weaker mucosal responses. Conversely, mucosal immunization generated stronger CD4 T
cell central memory (Tcm) responses in the colon. Intramuscular immunization generated higher levels of env-binding
antibodies, but neither produced neutralizing or cytotoxic antibodies. After mucosal SHIV challenge, both groups controlled
SHIV better than control animals. However, more animals in the ivag. group had lower viral set points than in in the i.m.
group. These data suggest mucosal vaccination may have improve protection against sexually-transmitted HIV. These data
also demonstrate that helper-dependent Ad vaccines can mediate robust vaccine responses in the face of prior immunity to
Ad5 and during four rounds of adenovirus vaccination.
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gene [3–5]. These vectors are also usually deleted for the Ad E3
immune evasion genes to make space for larger transgene
insertions.
More recently, helper-dependent Ad (HD-Ad) vaccines have
been tested as HIV vaccines [10,12]. Unlike FG-Ad vectors, all Ad
genes are deleted from HD-Ad to eliminate expression of
potentially inflammatory and immunogenic adenovirus proteins.
In gene therapy tests, HD-Ad vectors have been shown to be less
immunogenic, have improved safety, and mediate extended
expression of transgene products relative to FG vectors [13–16].
We performed the first head to head comparison of RC-Ad5,
FG-Ad5, and HD-Ad5 vector vaccines [12]. Direct comparison of
the three vector platforms in mice demonstrated that RC-Ad5 and
HD-Ad5 induced significantly higher immune responses than FGAd after i.m. or i.v. injection. This work also showed that HD-Ad5
with all Ad genes removed produced less liver damage than the
other vectors and lower anti-Ad T cell responses [12].

Introduction
Gene-based vaccines are one approach to vaccinate against
HIV-1 wherein viral genes are expressed from an expression
vector to stimulate the immune system (reviewed in [1]).
Adenoviruses (Ads) are one of a number of gene delivery vectors
that are being investigated as gene-based vaccines for HIV-1 [2–
11].
The earliest work with adenovirus vaccines utilized replicationcompetent Ad (RC-Ad) vectors with intact E1 early genes and
small HIV gene insertions into the viral genome [2]. These vectors
have the advantage of up to 10,000-fold vector amplification in
infected cells to increase antigen gene copy number and antigen
protein production. However, one limitation is the risk of frank
adenovirus infection with the use of these vectors. Most Ad HIV
vaccines have instead utilized first generation Ad (FG-Ad) vectors
that are rendered replication-defective due to deletion of the E1

PLOS ONE | www.plosone.org

1

July 2013 | Volume 8 | Issue 7 | e67574

Mucosal Vaccines against SHIV

Twelve female macaques were immunized intranasally with
161011 virus particles (vp) of adenovirus serotype 5 (Ad5)
expressing b-galactosidase to initiate immune responses to Ad5
just prior to vaccination with the species HD-Ad vectors (Fig. 1).
One group of four macaques was held as controls. One group of
four macaques was immunized by i.m. injection with 161011 vp of
HD-Ad6 expressing the JRFL gp140CF immunogen (HD-Ad6Env) as a systemic vaccine. Another group was immunized by
intravaginal (ivag.) lavage with 161011 vp of HD-Ad6-Env as a
mucosal vaccine. Three weeks later, both vaccine groups were
boosted by the same routes, this time by switching the serotype to
HD-Ad1-Env with the intent to avoid previously induced anti-Ad5
and anti-Ad6 immune responses.

Based on these data, HD-Ad vectors were tested as vaccines in
Ad5-immunized macaques by serotype-switching three species C
HD-Ads expressing HIV-1 env for three rounds of immunization
in Ad5-immune macaques [10,12]. This work demonstrated that
serotype-switching with three rounds of HD-Ad6, HD-Ad1, and
HD-Ad2 generates significantly higher antibody responses than
three rounds of immunization with the single-serotype HD-Ad5
[12]. After mucosal rectal SHIV-SF162P3 challenge, both
vaccinated groups controlled viremia significantly better than
control animals [10]. However, serotype-switching mediated
significantly lower peak viremia than immunization with only
the single serotype HD-Ad5 [10]. This is interesting given that
these HD-Ad5-immunized animals still mediated protection in the
face of several rounds of prior immunization with Ad5.
Since greater than 90% of HIV-1 infections occur at the
mucosal surface it is understood that mucosal immune responses
may be essential for prophylactic vaccination [17]. However, there
is disagreement in which routes of vaccination might induce
optimal mucosal immune responses to repel HIV. One hypothesis
is that the best way to induce the highest levels and affinities of
mucosal immune responses is to deliver the vaccines to mucosal
tissues. An alternate hypothesis is that strong systemic immune
responses will cross-over into mucosa to repel virus at this site of
entry. Both arguments are valid and there is conflicting evidence
for both hypotheses in different vaccine-infection systems.
In this study, we compared systemic intramuscular (i.m.)
vaccination with mucosal intravaginal (ivag.) vaccination with
HD-Ad vectors in the rhesus macaque model. Macaques were first
immunized with FG-Ad5. Groups of four macaques were then
immunized by the i.m. or ivag. route with HD-Ad6-Env
expressing the gp140CF immunogen of HIV-1 JRFL. They were
then boosted by the same routes with HD-Ad1-Env, HD-Ad5Env, and HD-Ad2-Env at 3, 8 and 9 week intervals and were then
challenged by the rectal route with 1000 TCID50 of CCR5-tropic
SHIV-SF162P3 at week 32 to test if either route of vaccination
mediated better immune correlates or protection after mucosal
challenge.

Systemic T Cell Responses in PBMCs
After two rounds of immunization, T cell responses mediated by
the vaccines were measured from PBMCs. PBMCs were
stimulated with the 15-mer peptide set for SF162P3 (NIH AIDS
Reagent Program) spanning the gp140 region expressed by the
JRFL gp140. 16105 PBMCs were stimulated separately with 3
pools of 50 to 70 peptides spanning the gp140 region and IFN-c
responses were detected by ELISPOT (Fig. 2). Since no notable
differences were observed between the 3 peptide pools and that the
pooling were arbitrary mixes, data is shown for the sum of IFN-c
spot forming units (SFU) for 36105 total input cells for simplicity
(Fig. 2).
Initial prime-boost with HD-Ad6 and HD-Ad1-Env by the i.m.
route generated 20 to 150 IFN-c SFUs per 36105 PBMCs (Fig. 2).
In contrast, intravaginal lavage with the same vaccines generated
weaker responses of 15 or less SFUs. These responses were
significantly weaker than those by the i.m. group (p,0.01 by
ANOVA). ELISPOT for perforin-secreting PBMCs showed
weaker responses that were not different between controls, i.m.,
and ivag. groups (Fig. 3).

Modification of Vaginal Immunization Method
The weak T cell responses after vaginal lavage with HD-Ad
suggested that this method might be ineffective and endanger the
over-all comparison of vaccine delivery to mucosa versus muscle.
Given this, and previous observations of improved adenovirus
transduction after direct needle injection into the cervical
epithelium, the last two mucosal immunizations were performed
by injection into this site (note: @ vs. # in Figs. 2 and 3). This
altered method would be unlikely to go systemic and would restrict
Ad exposure to mucosal tissues.
When this change in vaginal vaccine delivery was used for HDAd5-Env and HD-Ad2, they mediated substantially increased
IFN-c responses in PBMCs that approached the magnitude
observed in the i.m. group (Fig. 2).

Results
Comparison of Systemic and Mucosal HD-Ad Vaccination
in Ad5-immunized Macaques
We previously compared serotype switching HD-Ad6, 1, and 2
with single serotype vaccination with HD-Ad5 [10,12]. Groups of
four macaques were immunized with HD-Ads expressing only
HIV-1 envelope immunogen gp140CF immunogen from the
JRFL strain of the virus. This HIV env immunogen fuses gp120
and gp41 by deletion of their furin cleavage site and is also deleted
for gp160’s transmembrane domain to enable secretion from cells
[10,12]. The animals were challenged with SHIV-SF162P3
expressing the SF162P3 envelope that evolved during three
passages in monkeys [18–22]. ClustalW alignment of the gp140
domains of JRFL and SF162P3 reveals they have 88% identity in
amino acid sequence (Figure S1). Under these conditions, 10 of 11
animals became viremic after rectal challenge with 1000 TCID50
of SHIV-SF162P3 and were available for virologic comparison.
Comparison of these small groups of infected animals demonstrated statistically significant reductions in peak viremia between
the groups [23]. Based on this prior study in which statistical
differences were observed with the small set of animals, the current
study was initiated utilizing three groups of four macaques to
explore the role of vaccine route in protection against mucosal
challenge.

PLOS ONE | www.plosone.org

Vaccine-induced Systemic Cytokine Responses
Plasma cytokine levels of control and immunized animals were
measured at week 26 after vaccination, but before challenge
(Fig. 4A). Vaccination by both routes increased plasma IL-12 and
IFN-c levels significantly over levels in control animals (p,0.01 by
one way ANOVA). IL-6 levels were significantly higher in the i.m.
group than in controls (p,0.05), but not than in the ivag. group.
In contrast, IL-10 levels were significantly higher in the ivag.
group than control animals (p,0.001). IL-10 levels in the ivag.
group were also significantly higher than in the i.m. group
(p,0.01).
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Figure 1. Schedule of Vaccination and SHIV Challenge.
doi:10.1371/journal.pone.0067574.g001

responses were observed in PBMC CD8 cells expressing IL-2 or
IFN-c in both the T cell effector memory (Tem) and T cell central
memory (Tcm) compartments (Fig. 4B). In colon samples, the i.m.
group generated detectable levels of CD4 and CD8 Tem and Tcm
with stronger responses observed in CD4 cells. In contrast to the
i.m. group, the ivag.-immunized animals generated weaker PBMC
responses, but stronger responses in the colon. CD4 Tcm
responses in the colon were particularly higher in the ivag. group.
In this case, three of the four animals had dual functional IL-2/

Systemic and Mucosal Effector Memory and Central
Memory T Cell Responses
At week 26, PBMCs and colon biopsies were collected for flow
cytometry to analyze HIV-specific T cell compartments (Fig. 4B).
Aliquots of 0.25 to 16106 cells from the single cell suspensions of
PBMCs or colon biopsy samples were stimulated with HIV env
peptide-pulsed DC as in [24] and stained with CD3, CD4, CD8,
CD28, and CD95 for T cell subsets combined with IFN-c and IL2 to detect responses to HIV env. In the i.m. group, the strongest

Figure 2. IFN-c Secreting Cells from PBMCs. PBMCs in ELISPOT plates were stimulated with 3 pools of 50 to 70 peptides spanning the gp140
region of SF162 envelope for 36 h and IFN-c secreting spots were detected and counted. Responses in terms of IFN-c spot forming units (SFU) for 105
total input cells were determined for individual monkeys after subtracting background values of cells cultured in the medium. A) IFN-c secreting cells
from individual animals. B) Mean IFN-c secreting cells from each group.
doi:10.1371/journal.pone.0067574.g002

PLOS ONE | www.plosone.org
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Figure 3. Perforin Secreting Cells from PBMCs. PBMCs were analyzed by ELISPOT as in Fig. 2, but in this case were stained for perforin
production. A) Perforin secreting cells from individual animals. B) Mean perforin secreting cells from each group.
doi:10.1371/journal.pone.0067574.g003

IFN-c+ Tcm in the colon (H141, H225, and H245) and the fourth
did not (animal 48). In contrast, only one animal in the i.m. group
(animal 20) had IL-2/IFN-c+ Tcm in the colon. Comparison of
cytokine secreting cells in different compartments demonstrated
significantly higher colon CD4/Tcm cytokine secreting cells in
ivag.-immunized animals as compared to the same compartment
in i.m.-immunized animals (p,0.05 by T test). Conversely, CD8
Tem and Tcm cytokine-secreting cells from PBMCs were higher
in i.m.-immunized animals than in ivag.-immunized animals.

identity for most of the proteins. Two exceptions to this are hexon
and fiber proteins that have high serotype-specific variation.
Because of this, serotype-switching is generally thought to evade
antibodies primarily against hexon and to a lesser degree to evade
antibodies against fiber.
In these experiments, macaques were immunized five times with
four viruses from species C (Ad5, Ad6, Ad1, Ad5, and Ad2) and
their ability to drive anti-HIV T cell responses were quantitated.
After immunization with FG-Ad5, HD-Ad6 generated detectable
anti-Env T cell responses (Fig. 2 and 3). After immunization with
FG-Ad5, HD-Ad6, and HD-Ad1, HD-Ad5 itself generated robust
T cell responses in PBMCs. Finally, HD-Ad2 generated robust T
cell responses after four rounds of prior immunization with other
species C adenoviruses. These data suggest that several rounds of
exposure to adenoviruses from the same species does not prevent
the generation of T cell responses against immunogens expressed
by HD-Ad HIV vectors.

Immunization by Species C HD-Ad Vectors during
Multiple Rounds of Exposure to Species C Adenoviruses
Serotype-switching of Ad vaccines is an effective method to
evade pre-existing and vector-induced immune responses
[5,7,25,26]. However, concerns have been raised that any
adenovirus vector will stimulate cross-reactive T cell responses
against conserved epitopes in the hexon protein that can blunt
efficacy [27].
This HD-Ad vaccine study provides a unique model of the
effects of immunity against adenoviruses of related serotypes. Ad1,
2, 5, and 6 are all species C adenoviruses with high amino acid
PLOS ONE | www.plosone.org

Systemic and Mucosal Antibody Responses
Plasma and mucosal washes were collected two weeks after the
last immunization and were assayed for HIV-1 envelope-binding
4
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Figure 4. Systemic Cytokines, Peripheral and Mucosal T Cell Responses. A) Cytokine Responses. Heparinized plasma was collected and
analyzed for cytokine levels using a human cytometric bead assay (CBA) with standard curves for each cytokine. Statistical comparisons in A are by
one way ANOVA. B) T cell responses from PBMCs and colon biopsies. PBMCs and colon biopsies were collected at week 26 before challenge and CD4
and CD8 Tem and Tcm were analyzed for IL-2 and/or IFN-c production by flow cytometry (Table 1). Statistical comparisons in B are T test comparisons
of the "stack" of total cytokine-expressing cells for a given cell type (i.e. CD8 or CD4, Tcm or Tem).
doi:10.1371/journal.pone.0067574.g004

antibodies by ELISA (Fig. 5). The i.m. group generated
significantly higher anti- envelope antibody titers in the plasma
than the ivag. group (Fig. 5A, p,0.0001). Plasma and vaginal
washes were assayed for their ability to neutralize HIV-1 in vitro.
No significant neutralizing antibody titers were detected in the
plasma or vaginal washes after immunization as compared to the

PLOS ONE | www.plosone.org

unimmunized controls (Figure S2). Plasma PBMCs were assayed
for antibody-dependent cellular cytotoxicity (ADCC), but none of
this activity was observed. These data suggest that despite envbinding antibody production by the two vaccine routes, no other
antibody correlates were observed. This is consistent with previous
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Table 1. Mamu MHC Genotypes in Study Animals.

Animal

A01

A02

A08

A11

B01

B03

B04

B08

B17

B29

J545

2

2

2

+

2

2

2

2

2

2

J687

2

2

+

+

+

2

2

2

2

2

J691

2

2

+

+

2

2

2

2

+

+

J905

2

2

+

+

2

2

2

2

2

2

Rh20

2

+

2

2

2

2

2

2

2

2

Rh31

2

2

+

+

+

2

2

2

2

2

Rh34

2

2

+

+

2

2

2

2

+

+

Rh37

2

+

2

+

+

2

2

2

2

2

Rh48

2

2

+

2

2

2

2

2

2

2

H141

2

2

+

2

2

2

2

2

+

+

H225

2

+

2

2

2

2

2

2

2

2

H245

2

+

+

2

2

2

2

2

2

2

doi:10.1371/journal.pone.0067574.t001

162P3 and viral loads were monitored for 58 weeks after
challenge. Three of four control animals maintained viral set
points above 104 copies/ml (Fig. 6A). The exception was control
animal J691 whose viremia fell over 24 weeks to low levels.
Spontaneous control was not observed in controls in our previous
study [10], however, other studies have shown that SHIV
SF162P3 can be spontaneously controlled in approximately 25%
of unvaccinated animals [22]. Three of four i.m. immunized
macaques had lower viral set points than most controls, with one
(animal 31) having levels above 104 copies/ml. In the ivag. group,
three of the macaques had viral loads that fell precipitously over 20
weeks after challenge and fell at times below the level of detection.
One ivag. group macaque had high viral loads above 104 copies/
ml that were comparable to most of the controls.
When the viral loads between control and immunized animals
were compared by one way ANOVA, p values remained above
0.05 due in part due to spontaneous control of viremia in control
animal J691. One-tailed T test for viremia 2 weeks after challenge
at week 34 between control vs. i.m.-immunized animals gave p
= 0.067 and p = 0.070 for control vs. ivag. animals. T test for
viremia at week 55 between control vs. i.m.-immunized animals
gave p = 0.063 and p = 0.35 for control vs. ivag. animals. When
they were compared at week 80, the p value was 0.051 for control
vs. i.m.-immunized animals and was 0.11 for control vs. ivag.

experiments where multiple boosts with HD-Ad-Env generated
robust ELISA responses [12], but not neutralizing antibodies [10].
Recent data has suggested a possible correlation between
protection and variable loop binding antibodies in the RV144 trial
[28]. To test if similar binding antibodies might be present in the
vaccinated macaques, ELISAs against JRFL env were performed
in the presence or absence of competing 15-mer peptides
representing the variable loop domains of env. Under these
conditions, none of the variable peptides blocked binding of
macaque plasma antibodies to env (Figure S2).

Anti-adenovirus Antibodies
Plasma samples at 26 weeks were analyzed for neutralizing
antibodies against Ad1, Ad2, Ad5, and Ad6 after immunizations
with FG-Ad5, HD-Ad6, HD-Ad1, HD-Ad5, and HD-Ad2
(Fig. 5B). At this time point, i.m. immunizations neutralizing
titers over 1,000 against Ad6, 1, and 5, with 4-fold lower
antibodies against Ad2, the last vaccine utilized. In contrast,
samples from the vaginally-immunized animals had highest
antibody levels against Ad5, with intermediate levels against Ad1
and Ad2, and near background levels of anti-Ad6 activity.

Mucosal Challenge with CCR5-Tropic SHIV-162P3
Eight weeks after the last HD-Ad immunization, the animals
were challenged by the rectal route with 1000 TCID50 of SHIV-

Figure 5. Antibodies Against HIV-1 Env and Species C Adenoviruses. A) Anti-env antibodies. Plasma was collected from each group and
these were analyzed for env-binding antibodies by ELISA against JRFL env (matching the vaccine). B) Anti-adenovirus neutralizing antibodies. Plasma
from week 26 was serially diluted and tested for its ability to neutralize HD-Ad vectors expressing luciferase in vitro.
doi:10.1371/journal.pone.0067574.g005

PLOS ONE | www.plosone.org
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Figure 6. SHIV Viremia After Rectal Challenge. A) SHIV viral genomes were quantitated from plasma at the indicated times after challenge for
each animal. The reported minimal detection for this assay of 30 meq./ml is indicated by a dashed gray line. B) Comparison of mean SHIV viral loads
for controls, i.m. vaccinated, ivag. vaccinated, and the combined mean for all vaccinated animals. Asterisks indicate time points at which p,0.05 for
controls as compared to combined vaccinated animals by T test. I.m. and ivag. only groups did not reach this p value.
doi:10.1371/journal.pone.0067574.g006

animals. These data suggest that comparison with larger groups of
animals might reach better statistical significance.
The animals remained healthy over the 90 weeks of the
experiment. Follow up after 90 weeks showed that the animals
remained healthy with the exceptions of animal #48 from ivag.
group and J545 from control group. These animals had to be
euthanized due to AIDS-like symptoms.
At the end of the study, the macaques were genotyped for major
histocompatibility complex (MHC) alleles (Table 1). MHC alleles
were varied within the animals and no overt association was
observed between each animal’s genotype and control of SHIV.
PLOS ONE | www.plosone.org

Individual Responses to Immunization and Challenge
After last immunization at week 26, no neutralizing or ADCC
antibody responses were observed in the plasma or vaginal washes
of the animals (Figure 2 and data not shown). 100-fold higher envbinding antibody titers were observed in plasma from the i.m.
group when compared to the ivag. group (Fig. 5A). However, three
of the four animals in the ivag. group have lower viremia than the
i.m. group, suggesting that env binding antibodies were not
associated with reductions in viral load.
Thirteen weeks after challenge (week 45), cellular immune
responses in controls were two to three-fold lower than in the i.m.
7
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and ivag. groups (Fig. 2 and 3). Over the next 12 weeks, most of
the control and vaccinated animals mounted increasing levels of
IFN-c responses. For 50 weeks after challenge, most IFN-c
responses declined, but a few animals’ responses increased later. In
contrast to IFN-c ELISPOT responses from PBMCs, perforin
ELISPOT responses from these cells showed low magnitude in all
of the animals after challenge with some increases for animals 31
and 34 in the i.m. group 50 weeks after challenge.
Control animals J545, J687, and J905 had high plasma viremia
levels, whereas J691’s levels were lower (Fig. 2B). All but J687 had
detectable IFN-c responses in PBMCs after challenge, but these
did not appear to track with high or low viral loads.
The i.m. immunized animals had significant levels of anti-HIV
cellular immunity in PBMCs by ELISPOT prior to the virus
challenge (Fig. 2 and 3). SHIV challenge boosted these anti-HIV
cellular responses. The ivag. immunized animals that showed the
best control over plasma viremia, H225 and H245, had the highest
levels of anti-HIV IFN-c responses at week 44, 12 weeks after
challenge (Fig. 2A). The outlier in this group animal 48 that did
not control the virus, had similar anti-HIV IFN-c responses before
challenge as compared to the other animals. However, animal 48’s
anti-HIV IFN-c responses after challenge remained lower than the
other animals in this group.
The i.m. immunized animals had the highest numbers of
cytokine-secreting CD8 Tem and Tcm in PBMCs (Fig. 4B). In
contrast, ivag. animals had low numbers of these cells, yet
controlled virus as well or better than the i.m.-immunized animals
suggesting that these cells may not be most associated with viral
control. Three of the four intravaginally-immunized macaques
had detectable dual functional IL-2/IFN-c+/+ CD4 Tcm in the
colon (H141, H225, and H245) 6 weeks before challenge, but
animal 48 that did not control viremia did not have these
responses (Fig. 2A and B). Animals H141, H225, and H245 had
the lowest viremia of all macaques in the study whereas animal 48
had high levels of virus (Fig. 2B). Within the i.m. group, only
animal 20 had detectable IL-2/IFN-c+/+ Tcm in the colon.
Animal 20 also had the lowest viremia in the i.m. immunized
group. Taken together, these three ivag. and one i.m. immunized
animals had both the lowest viremia after mucosal challenge and
also had the highest IL-2/IFN-c+/+ CD4 Tcm responses in the
colon of all the animals.

Ad applied by this method might not leak beyond the mucosal
site, the qualitatively different immune responses that were
observed suggest different route effects were maintained.
Both routes of immunization induced elevated IL-12 and IFN-c
cytokines in the blood of the animals to similar levels that are
thought to support TH1 cellular immune responses. The i.m. route
produced stronger IL-6 levels than controls while the ivag. route
generated stronger IL-10 levels than controls and the i.m. group.
IL-6 is an inflammatory cytokine that is also strongly associated
with early innate immune responses to many infections, but also
against adenoviruses [29]. IL-10 is generally thought to bias
responses towards TH2, but may also be associated with Treg
responses.
Neither route generated antibodies with neutralizing, ADCC
activities. ADCC was measured using whole PBMCs, so it is
possible that stronger responses might be detected on purified NK
cells. We were unable to detect V1/V2 binding antibodies as were
observed in the RV144 trial [28] in our samples. Both routes of
immunization produced envelope-binding antibodies in the
plasma as measured by ELISA. However, the i.m. route generated
plasma titers that were 100-fold higher than those generated by
the ivag. route, yet more animals in the ivag. group had lower viral
loads than in the i.m. group.
As expected, T cell responses from PBMCs were generally
stronger after i.m. immunization than by ivag. immunization
before challenge. These T cell responses climbed to higher
frequencies after challenge than in control animals suggesting that
vaccine groups were undergoing robust anamnestic recall
responses. Of these, the ivag. group surprisingly had slightly
higher responses relative to the i.m. group when compared to
controls.
When cytokine production was assessed in Tem and Tcm
cells from PBMCs and from colon biopsies before challenge,
marked differences between the groups were observed. The i.m.
route generated more robust IL-2 and IFN-c responses in
PBMC CD8 Tem and Tcm consistent with ELISPOT data. In
contrast, CD8 responses in the colon samples were somewhat
stronger in the ivag. group than the i.m. route group. CD4
responses were infrequent from PBMCs, but were more
frequent for both groups in the colon samples. All four animals
in the ivag. group generated CD4 Tcm cells in the colon. Three
of the four i.m. group animals generated Tcm cells, but these
were all at lower percent positive than all of the ivag. samples.
When considering dual function IL-2/IFN-c+/+ CD4 Tcm cells,
three of four ivag. animals generated these central memory cells
in the colon, whereas only one i.m. group animal generated
these cells. Higher IL-2/IFN-c+/+ CD4 Tcm cells correlated
negatively with viral loads at weeks 55 and 80, suggesting them
play a role in controlling viremia after mucosal infection by
SHIV.
These data observing stronger PBMC T cell responses after
i.m. immunization and better T cell responses in the colon after
ivag. immunization are consistent with the hypothesis that
systemic immunization drives better systemic immune responses
and mucosal immunization drives better mucosal immune
responses. Systemic and mucosal vaccination both generated
immune correlates, with some indication that the ivag. route of
immunization generated better protection against challenge in
this small set of animals. These data support additional studies
to determine if mucosal immunization does indeed have
advantages when vaccinating against the mucosal pathogen
HIV-1.

Discussion
This study was intended to compare systemic versus mucosal
vaccines for their abilities to repel mucosal challenge by SHIV.
We compared systemic (i.m.) vaccination with mucosal (ivag.)
vaccination with HD-Ad vectors in the rhesus macaque model.
We modeled a scenario of prior immunity to Ad5 by
immunizing macaques with Ad5 before vaccination. The
macaques were then immunized by the i.m. or ivag. route
with HD-Ads expressing only the HIV envelope immunogen.
The animals were immunized four times by the two routes with
serotype switching of species C HD-Ads, 6, 1, 5, and 2 prior to
challenge by the rectal route.
One caveat to this comparison is that we altered the vaginal
delivery method at immunization three from lavage to cervical
epithelial injection because of concerns with how well the
vaccines were ‘‘taking’’. While the method changed, we believe
this shallow injection into the cervix maintains the ‘‘mucosal
route’’, since the injection is restricted to this locale. One can
draw a parallel between this and a natural HIV infection where
the vaginal epithelial is also thought to have small breaks that
absorb incoming virus. While we cannot formally exclude that
PLOS ONE | www.plosone.org
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were performed by injection into the vaginal wall near the cervix
using a 20 gauge catheter guided by an Otoscope.

Materials and Methods
Adenoviruses
HD-Ad1, 2, 5, and 6 viruses expressing the gp140 form of HIV1 JRFL were produced as previously described [12]. Briefly, HDAd5-env vector was transfected into a 60-mm dish of Creexpressing 116 cells expressing Cre recombinase as in [30]. The
transfected cells were infected a day later with the E1-deleted Ad5
helper virus AdNG163 whose packaging signal is flanked by loxP
sites [30] for deletion in the Cre cells. Lysates were subsequently
amplified by serial infections with AdNG163 in 116 cells. CsClbanded HD-Ad were then produced from 3 liters of 116 cells
producing HD-Ad preps with E1 -deleted helper contamination
less than 0.02% [30]. HD-Ad1, 2, and 6 vectors were generated
with helper viruses Ad1LC8cCEVS-1, Ad2LC8cCARP [31], and
Ad6LC8cCEVS-6, respectively that were generously provided by
Carole Evelegh and Frank L. Graham (McMaster University).

Collection of Samples
Samples were collected at each time point indicated before any
immunization or procedure. Peripheral venous blood samples
were collected in EDTA or sodium heparin. Before the separation
of peripheral blood mononuclear cells (PBMC) from the blood
samples, plasma was separated and stored immediately at -80uC.
Peripheral Blood Mononuclear Cells (PBMCs) were prepared
from the blood on Ficoll-Hypaque density-gradients.

Colon Biopsies
The macaques were fasted for a minimum of 12 hours prior to
the having colon biopsy to evacuate the stomach, duodenal, and
proximal jejunal contents. They were then anesthetized with 3–
5 mg/kg of Telazol, and placed in left lateral recumbency with a
mouth guard to protect the endoscope. Using a human pediatric
flexible endoscope with up to 7.8 mm in diameter, the gastroscopy
was accomplished by advancing the endoscope through the colon
and 1 to 2 mm biopsies were performed at the desired sites with up
to 10–15 biopsies at each time point. In this procedure the monkey
were given penicillin post biopsy for one day and 0.005 to
0.01 mg/kg Buprenorphine for 2 days. The monkey’s health,
appetite, and stool were monitored twice per day.

Animals
All animal experiments were approved by the Institutional
Animal Care and Use Committee at the University of Texas MD
Anderson Cancer Center and were carried out according to the
provisions of the Animal Welfare Act, PHS Animal Welfare
Policy, and the principles of the NIH Guide for the Care and Use
of Laboratory Animals, and the policies and procedures of the
University of Texas MD Anderson Cancer Center. Twelve adult
female rhesus macaques (Macaca mulatta) of Indian origin were
maintained in the specific pathogen-free breeding colony at the
Michael Keeling Center for Comparative Medicine and Research
of The University of Texas MD Anderson Cancer Center, Bastrop
TX. The chamber size for the animals was 449W 6 889H 6
160’D. All monkeys were given water ad libitum and were fed a
commercial monkey diet (Harlan). Additional enrichment is
provided in the form of manipulanda, visual stimulation or
auditory stimulation and combinations thereof. Animals were
monitored daily, including weekends and holidays. Anesthetics/
analgesics were used to minimize any discomfort, distress, pain,
and injury the animal might experience. As an endpoint, animals
were euthanized with ketamine (11 mg/kg) followed by Beuthanasia (1 ml/10 lb)]. If any animal was moribund, unresponsive to
treatment, could not eat or drink, was severely sick, or had
symptoms of SAIDS, it was euthanized as per guidelines. The
animals were anesthetized during procedures to minimize
discomfort. Human PBMCs were obtained under approval of
the Duke University Health System Institutional Review Board.
Written informed consent was provided by study participants and/
or their legal guardians.

Isolation of Lymphocytes from Colon Biopsies
Colon biopsy specimens were washed once with cold PBS and
the tissues were incubated at 37uC in RPMI 1640 containing 5%
fetal bovine serum supplemented with type IV collagenase (SigmaAldrich) at 300 U/ml and DNase I at 15ug/ml with gentle
shaking. The released cells were filtered through a 70 mm nylon
mesh screen. Lymphocytes were purified on Percoll gradients (35–
65%) at 1,500 RPM for 25 min. Lymphocytes were collected
above 65% Percoll layers and washed two times before processing
for staining.

Collection of Mucosal Washes
Nasal secretions were collected using a phosphate buffered
saline moistened sterile swab. The swab was placed in the nose,
rotated and the swab was incubated in a collection tube with 1 ml
of cold PBS to release the sample. Vaginal secretions were
collected by lavage of the vagina with 10 ml of PBS with a 10 ml
syringe.

ELISA
To measure anti-Env plate binding antibodies, ELISAs were
performed on macaque plasma and nasal washes after the last
immunization as previously described [24]. Briefly, Immulon 4
HBX plates (Thermo, Milford, MA) were coated with 100 ml of
HIV-1 envelope (Env) protein, JRFL-gp140CF and SF162 gp120
(NIH AIDS Reagent and Repository) at 1 mg/ml in PBS for 2
hours at room temperature (RT). The plates were blocked for 1 h
with 1.0% BSA for 1 hour. Plasma and nasal washes were diluted
1:100 and 1:4, respectively, in PBS with 1.0% BSA and added to
the plate for 1 h at RT. The plates were washed with 5 times PBS
and 100 ml of Goat anti-monkey (H&L) HRP conjugated antibody
(Pierce, Rockford, IL) diluted 1:2500 in PBS with 1.0% BSA was
added to the plate for 1 h at RT. The plates were washed 5 times
with PBS and 100 ml of 1 Step Ultra TMB-ELISA substrate
(Pierce, Rockford, IL) was added for 1 h at RT. The reaction was
stopped with 50 ml of 2 M sulfuric acid and analyzed at 450 nm
using a Beckman Coulter DTX 880 Multimode Detector.

Induction of Pre-existing Anti-Ad5 Immunity
Groups of four macaques were used in these experiments. The
macaques were sedated and immunized intranasally with
161011 vp of Adenovirus serotype 5 expressing b-galactosidase
(Ad-LacZ). Blood, nasal lavages, vaginal lavages and colon biopsies
were collected pre-immunization.

Systemic and Mucosal HD-Ad-Env Immunization
Macaques were immunized intramuscularly (i.m.) or intravaginally (ivag.) with 1011 vp of HD-Ad6-JRFL, HD-Ad1-JRFL, HDAd5-JRFL, and HD-Ad2-JRFL at weeks 4, 7, 15 and 24,
respectively (Fig. 1). The first two intravaginal immunizations
involved simple application of 0.5 ml of the virus solution in PBS
onto the vaginal epithelium. Because of concerns that this might
not mediate robust transduction [32], the intravaginal immunizations with HD-Ad5-JRFL and HD-Ad2-JRFL on weeks 15 and 24
PLOS ONE | www.plosone.org
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temperature. Spots representing individual cells secreting IFN-c or
perforin were developed using BCIP/NBT substrate as per
protocol provided by manufacturer. The plates were washed to
stop development and the spots were counted by an independent
agency (Zellnet Consulting, New Jersey, NJ). The responses in
terms of IFN-c or perforin spot forming cells (SFC) for 105 total
input PBMC were determined for individual monkeys after
subtracting background values of cells cultured in the medium.
The cut off value for determining the positive response in the assay
is defined as a minimum of 10 spots that is twice the number
observed in cells cultured in the medium. Data is represented as
SFUs per 105 PBMCs.

Assay for Neutralization of HIV and SHIV
Neutralization was measured as a reduction in luciferase
reporter gene expression after a single round of infection in
TZM-bl cells as described [33,34]. TZM-bl cells were obtained
from the NIH AIDS Research and Reference Reagent Program,
as contributed by John Kappes and Xiaoyun Wu. Briefly, 200
TCID50 of virus was incubated with serial 3-fold dilutions of test
sample in duplicate in a total volume of 150 ml for 1 hour at 37uC
in 96-well flat-bottom culture plates. Freshly trypsinized cells
(10,000 cells in 100 ml of growth medium containing 75 mg/ml
DEAE dextran) were added to each well. One set of control wells
received cells+virus (virus control) and another set received cells
only (background control). After a 48 hour incubation, 100 ml of
cells was transferred to a 96-well black solid plates (Costar) for
measurements of luminescence using the Britelite Luminescence
Reporter Gene Assay System (PerkinElmer Life Sciences).
Neutralization titers are the dilution at which relative luminescence units (RLU) were reduced by 50% compared to virus
control wells after subtraction of background RLUs. Assay stocks
of molecularly cloned Env-pseudotyped viruses were prepared by
transfection in 293T cells and were titrated in TZM-bl cells as
described [33]. The clade B reference Env clones were described
previously [33].

Intracellular Cytokine Assays
PBMC or single cell suspensions of colon biopsies were
incubated at 37uC in a 5% CO2 incubator for 6 h in the presence
of RPMI 1640–10% FBS medium alone (unstimulated), a pool of
15-mer env peptides (5 mg/ml each peptide), or with PMA and
ionomycin (5 mg/ml; Sigma-Aldrich) as a positive control. All
cultures contained monensin (GolgiStop; BD Biosciences) as well
as 1 ug/ml anti-CD49d (BD Biosciences). The cultured cells were
stained with monoclonal antibodies (MAbs) specific for cell surface
molecules (CD3, CD4, CD8, CD28, and CD95) and an Aqua to
discriminate live from dead cells as in [37]. After fixation with
Cytofix/Cytoperm solution (BD Biosciences), cells were permeabilized and stained with antibodies specific for IFN-c, and IL-2.
Labeled cells were fixed in 1.5% formaldehyde-PBS. Samples were
collected on an LSR II instrument (BD Biosciences) and were
analyzed using FlowJo software (Tree Star). Approximately
200,000 to 1,000,000 events were collected per sample (see Figure
S3 for examples). The background level of cytokine staining varied
from sample to sample but was typically ,0.01% of the CD4+ T
cells and ,0.05% of the CD8+ T cells. Samples were considered
positive when the percentage of cytokine-staining cells was at least
twice that of the background. ICS assays were performed on
PBMC and single cell suspensions from colon biopsies obtained on
week 26.

Antibody Dependent Cellular Cytotoxicity (ADCC)
The presence of ADCC-mediating antibody responses was
measured using PBMCs as previously reported using the flowbased GTL ADCC assay [35]. The testing of samples was
conducted using SF162 recombinant gp120 (GeneBank No.
AAT67508;
ImmuneTechnology,
Corp)
to
coat
CEM.NKR.CCR5 target cells. PBMC from a normal human
donor were utilized as source of effector cells. The results were
analyzed to determine the maximum ADCC activity and the titer
of ADCC Ab. The cut off for positive responses was set at 8%
GTL activity.

Cytokine Measurements
Non-Human Primate Cytokine kit with IL-2, IL-4, IL-6, IL-10,
IL-12/23(p40), IFN-c and TNF-a was purchased from Millipore
Corporation (Billerica, MA). Plasma concentrations of cytokines
were determined according to the manufacturers’ protocols.
Multianalyte profiling was performed on the Bio-Plex 200 system
and the micro plate Platform (Luminex X MAP technology).
Calibration microspheres for classification and reporter readings
as well as sheath fluid were also purchased from Millipore
Corporation. Acquired fluorescence data were analyzed by the
Bio-Plex manager 5.0.

Intrarectal Exposure to SHIV
To evaluate for protective efficacy and immunological correlates, all monkeys were challenged by intrarectal inoculation of
1,000 TCID50 of SHIV-SF162P3 from the NIH AIDS Reagent
Program. The monkeys were fasted for a minimum of 24 hours
prior to exposure. The animals were anesthetized (10 mg/kg of
body weight ketamine intramuscularly [i.m.] and 0.5 mg/kg
xylazine i.m.) and were placed in a sternal position with the pelvis
propped up at an approximately 45u angle. A lubricated infant
feeding catheter was inserted gently into the rectum of the animal
approximately 4 to 6 inches without causing any injury. First 5 ml
of diluent (PBS) was gently flushed through the catheter, and then
0.5 ml of the virus was injected through the catheter, followed by a
0.5 ml flush with diluents. The animal was returned to its cage and
kept tilted at 450 angle until it fully recovered from anesthesia.

ELISPOT Assay For Detecting Antigen-Specific IFN-c And
Perforin Producing Cells
Freshly prepared PBMC were used for the IFN-c or perforin
ELISPOT assay as described previously [36]. PBMCs were either
stimulated with synthetic peptides pools, with Ad expressing env,
or with Con A (5 mg/ml) as positive control reagent. The SF162P3
overlapping env 15-mer peptide set (NIH AIDS Reagent Program)
was used as 3 pools of 50 to 70 peptides spanning the gp140
region. PBMCs (1 x 105) were seeded in duplicate wells of 96-well
plates (polyvinylidene difluoride backed plates, MAIP S 45,
Millipore, Bedford, MA) coated with anti-IFN-c or anti-perforin.
The cells were incubated in the presence of the various antigens
for 36 h at 37uC. The cells were then removed, the wells washed,
and then incubated with 100 ml of ALP conjugated secondary
anti-IFN-c or streptavidin-ALP for perforin assay for 2 h at room
PLOS ONE | www.plosone.org

Viral Load Determination
SHIV viral loads from the blood were determined by
determining viral RNA copy numbers by real-time RT-PCR
analyses. These assays were performed at the NIH Core Facility
by Dr. Jeff Lifson’s group. The threshold sensitivity of the assay is
30 viral RNA copy-equivalents/ml of plasma, and the inter-assay
variation is ,25% (coefficient of variation).
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Figure S2 Anti-Env ELISA in the Presence of Competing
Env Peptides.
(TIFF)

Major Histocompatibility Typing of Macaques in the
Study
After completion of the study, PBMCs from study macaques
were evaluated for Mamu haplotypes by the AIDS Vaccine
Research of Dr. David Watkins at the University of Miami. MamuA01, A02, A08, A11, B01, B03, B04, B08, B17, and B29 alleles by
PCR (PCR Experiment # 121211 Mayo Clinic (Dr. Barry)).

Figure S3 Flow cytometry for Tcm and Tem. A) Gating
strategy. B) Representative flow cytometry scatter plots.
(TIFF)
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